Mainstay Medical Announces Limited Commercial Launch of ReActiv8® in the U.S.

Mainstay Medical Holdings plc today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation™ system to treat intractable chronic low back pain. The ReActiv8 system will be available in the U.S. through ReActiv8-certified physicians commencing in the summer of 2021.